VivoSeq
Other

Hemoglobin SC Disease

2

Pipeline Programs

0

Active Trials

0

Companies Involved

Hemoglobin SC Disease is an early-stage landscape with 2 programs across 0 companies.

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

0/100

Attrition Rate

100/100

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs

Trial Status

3

clinical trials

Terminated3 · 100%

Trial Activity

Treatment of Hemoglobin SC Disease With Hydroxyurea
Terminated··Phase 2·NCT02336373·32 enrolled
Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate
Terminated··Phase 2·NCT00040456·12 enrolled
Treatment of Adult Patients With Hemoglobin SC Disease (SCYTHE)
Terminated··Phase 2·NCT02640573·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)